Special Issue

Emerging Trends in Pulmonary Fibrosis

Message from the Guest Editors

Interstitial lung disease (ILD) is characterized by an admixture of fibrosis and inflammation infiltrating the interstitium of the lung in a diffuse fashion. There are many different causes of ILD, the more common and severe of which are characterized mostly by fibrosis. Idiopathic pulmonary fibrosis (IPF) is the most common of the fibrotic ILDs and carries a prognosis that is worse than many forms of cancer. The diagnostic and treatment paradigm of IPF and other fibrotic ILDs continues to evolve. Making an accurate diagnosis of IPF can be challenging and often requires a multidisciplinary approach. The advent of antifibrotic therapy over the past decade has changed the landscape of therapy for IPF and appears to have altered the natural disease course. Recent data suggest that pulmonary hypertension, a common complication, might be a viable target for therapy when it supervenes in IPF and other ILDs. The aim of this Special Issue is to highlight and contextualize some of these recent advances in the field of pulmonary fibrosis.

Guest Editors

Prof. Dr. Steven D. Nathan

Inova Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA, USA

Dr. Christopher King

Advanced Lung Disease and Transplant Clinic, Inova Fairfax Hospital, 3300 Gallows Rd, Falls Church, VA 22042, USA

Deadline for manuscript submissions

closed (30 September 2021)



Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 5.7 Indexed in PubMed



mdpi.com/si/58306

Journal of Clinical Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jcm@mdpi.com

mdpi.com/journal/

icm





Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 5.7 Indexed in PubMed





About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine*'s (*JCM*) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.3 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2024).